Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma
Nurix Therapeutics (NRIX) announced upcoming presentations of clinical data for their drug bexobrutideg (NX-5948) at two major scientific conferences in June 2025. The data comes from ongoing Phase 1a/b clinical trials studying the drug's effects on patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia.
The presentations will take place at the European Hematology Association Congress (EHA 2025) in Milan and the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano. The data will be featured in two posters at EHA 2025 and in both an oral presentation and poster at 18-ICML, focusing on bexobrutideg's clinical responses and safety profile as a novel Bruton's tyrosine kinase (BTK) degrader.
Nurix Therapeutics (NRIX) ha annunciato la presentazione imminente di dati clinici sul loro farmaco bexobrutideg (NX-5948) in due importanti conferenze scientifiche previste per giugno 2025. I dati provengono da studi clinici di Fase 1a/b in corso, che valutano gli effetti del farmaco su pazienti con leucemia linfatica cronica (CLL) recidivante/refrattaria e macroglobulinemia di Waldenström.
Le presentazioni si terranno al Congresso della European Hematology Association (EHA 2025) a Milano e al 18° Congresso Internazionale sul Linfoma Maligno (18-ICML) a Lugano. I dati saranno presentati in due poster all'EHA 2025 e sia in una presentazione orale che in un poster all'18-ICML, con un focus sulle risposte cliniche e il profilo di sicurezza di bexobrutideg, un nuovo degradatore della tirosina chinasi di Bruton (BTK).
Nurix Therapeutics (NRIX) anunció próximas presentaciones de datos clínicos de su medicamento bexobrutideg (NX-5948) en dos importantes congresos científicos en junio de 2025. Los datos provienen de ensayos clínicos de Fase 1a/b en curso que estudian los efectos del fármaco en pacientes con leucemia linfocítica crónica (LLC) en recaída/refractaria y macroglobulinemia de Waldenström.
Las presentaciones se realizarán en el Congreso de la Asociación Europea de Hematología (EHA 2025) en Milán y en la 18ª Conferencia Internacional sobre Linfoma Maligno (18-ICML) en Lugano. Los datos se mostrarán en dos pósters en EHA 2025 y en una presentación oral y póster en 18-ICML, centrados en las respuestas clínicas y el perfil de seguridad de bexobrutideg, un nuevo degradador de la tirosina quinasa de Bruton (BTK).
Nurix Therapeutics (NRIX)가 2025년 6월에 열리는 두 개의 주요 과학 학회에서 자사의 약물 bexobrutideg (NX-5948) 임상 데이터 발표를 앞두고 있다고 발표했습니다. 이 데이터는 재발성/불응성 만성 림프구성 백혈병(CLL) 및 월덴스트룀 거대글로불린혈증 환자를 대상으로 진행 중인 1a/b상 임상시험에서 나온 것입니다.
발표는 밀라노에서 열리는 유럽혈액학회 총회(EHA 2025)와 루가노에서 열리는 제18회 악성 림프종 국제학회(18-ICML)에서 진행됩니다. EHA 2025에서는 두 개의 포스터로, 18-ICML에서는 구두 발표와 포스터로 bexobrutideg의 임상 반응 및 안전성 프로필에 대해 발표할 예정이며, 이는 새로운 브루톤 티로신 키나제(BTK) 분해제입니다.
Nurix Therapeutics (NRIX) a annoncé des présentations à venir de données cliniques concernant leur médicament bexobrutideg (NX-5948) lors de deux grandes conférences scientifiques en juin 2025. Ces données proviennent d’essais cliniques de phase 1a/b en cours, étudiant les effets du médicament chez des patients atteints de leucémie lymphoïde chronique (LLC) en rechute/réfractaire et de macroglobulinémie de Waldenström.
Les présentations auront lieu au Congrès de l’European Hematology Association (EHA 2025) à Milan et à la 18e Conférence Internationale sur le Lymphome Malin (18-ICML) à Lugano. Les données seront présentées sous forme de deux posters à l’EHA 2025, ainsi que lors d’une présentation orale et d’un poster à l’18-ICML, mettant en avant les réponses cliniques et le profil de sécurité de bexobrutideg, un nouveau dégradeur de la tyrosine kinase de Bruton (BTK).
Nurix Therapeutics (NRIX) gab bekannt, dass klinische Daten zu ihrem Medikament bexobrutideg (NX-5948) auf zwei wichtigen wissenschaftlichen Konferenzen im Juni 2025 präsentiert werden. Die Daten stammen aus laufenden Phase 1a/b-Studien, die die Wirkung des Medikaments bei Patienten mit rezidivierender/refraktärer chronischer lymphatischer Leukämie (CLL) und Waldenström-Makroglobulinämie untersuchen.
Die Präsentationen finden auf dem European Hematology Association Kongress (EHA 2025) in Mailand und der 18. Internationalen Konferenz zum malignen Lymphom (18-ICML) in Lugano statt. Die Daten werden auf zwei Postern bei EHA 2025 sowie in einer mündlichen Präsentation und einem Poster bei der 18-ICML vorgestellt, wobei der Fokus auf den klinischen Reaktionen und dem Sicherheitsprofil von bexobrutideg als neuem Bruton's Tyrosinkinase (BTK)-Degrader liegt.
- None.
- None.
Insights
Nurix's BTK degrader bexobrutideg shows promising efficacy and safety in blood cancer trials, advancing their targeted protein degradation platform.
The upcoming data presentations for bexobrutideg (NX-5948) represent a significant milestone in Nurix's development of targeted protein degradation therapeutics. The presentation titles notably contain positive signals about the drug's performance, specifically highlighting "rapid and durable clinical responses" in CLL and "high clinical activity and tolerable safety" in Waldenström macroglobulinemia.
This BTK degrader targets the Bruton's tyrosine kinase pathway, which is critical in B-cell malignancies. Unlike BTK inhibitors which only block enzyme activity, degraders like bexobrutideg completely remove the protein from cells, potentially offering advantages in overcoming resistance mechanisms that develop with inhibitors.
The Phase 1a/b data being presented spans two difficult-to-treat patient populations with relapsed/refractory disease - patients who have limited treatment options and typically poor prognoses. The terminology used in the abstract titles suggests the response rates are clinically meaningful, with both efficacy signals and acceptable safety profiles.
The selection for presentation at both EHA and ICML, with inclusion as an oral presentation at ICML, indicates the data is considered valuable by peer reviewers. Oral presentations are typically reserved for more impactful findings compared to poster presentations. The involvement of investigators from multiple prestigious institutions (City of Hope, University of Cincinnati, Royal Marsden) adds credibility to the research.
While specific response rates, durability metrics, and safety details aren't disclosed in this release, the positive framing of the presentation titles suggests the full data may support further clinical development toward potential registration trials if the complete results align with these descriptions.
SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that data from the Company’s ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia will be presented at two major upcoming scientific conferences.
Data will be featured in two posters at the European Hematology Association 2025 Congress (EHA 2025), taking place June 12–15, 2025, in Milan, Italy, and in an oral presentation and poster at the 18th International Conference on Malignant Lymphoma (18-ICML), to be held June 17–21, 2025, in Lugano, Switzerland.
EHA 2025 Presentation Details:
Title: Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed refractory CLL: updated findings from an ongoing Phase 1a Study
Presenting author: Zulfa Omer, M.D., Assistant Professor Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH, USA
Session title: Poster Session 1
Session date and time: Friday, June 13 (18:30 - 19:30 CEST)
Abstract ID: PF571
Title: Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in patients with Waldenström macroglobulinemia
Presenting author: Dima El-Sharkawi, M.B., B.S., M.A., Ph.D., MRCP FRCPath, Consultant Haematologist, Royal Marsden NHS Foundation Trust, Sutton, UK
Session title: Poster Session 2
Session date and time: Saturday, June 14 (18:30 - 19:30 CEST)
Abstract ID: PS1883
18-ICML Oral Presentation Details:
Title: Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed refractory CLL: updated findings from an ongoing Phase 1a Study
Presenter: Alexey Danilov, M.D., Ph.D., Marianne and Gerhard Pinkus Professor in Early Clinical Therapeutics, Co-Director of Toni Stephenson Lymphoma Center, City of Hope National Medical Center, Duarte, CA, USA
Session title: 18: New Drugs
Session date and time: Saturday, June 21 (9:30 CEST).
Abstract ID: 093
18-ICML Poster Presentation Details:
Title: Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in patients with Waldenström macroglobulinemia
Presenting author: David Lewis, M.D., Consultant Hematologist, Derriford Hospital; Associate Professor, Derriford Hospital, Plymouth, UK
Session title: Poster Session (Odd numbered posters)
Session date and time: Thursday, June 19 (10:00-18:00 CEST)
Abstract ID: 437
About Bexobrutideg (NX-5948)
Bexobrutideg is an investigational, orally bioavailable, brain penetrant, small molecule degrader of BTK. Bexobrutideg is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies. Additional information on the ongoing clinical trial can be accessed at clinicaltrials.gov (NCT05131022).
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the planned timing for the provision of updates and findings from the clinical trial of bexobrutideg at EHA 2025 and ICML 2025, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2025, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Nurix’s business and results of operations, which could, in turn, have a significant and adverse impact on Nurix’s stock price. Nurix cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.
Contacts:
Investors
Kris Fortner.
Nurix Therapeutics, Inc.
Kfortner@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
What is bexobrutideg (NX-5948) and what is it being developed for by Nurix Therapeutics (NRIX)?
Where and when will Nurix Therapeutics (NRIX) present its clinical trial data for bexobrutideg in 2025?
What phase of clinical trials is bexobrutideg (NX-5948) currently in?
How many presentations will Nurix Therapeutics (NRIX) deliver about bexobrutideg at these conferences?
